Protective Effect of Qiliqiangxin Capsule on Energy Metabolism and Myocardial Mitochondria in Pressure Overload Heart Failure Rats

Table 2

The changes of body weight, heart weight/body weight ratio (HW/BW), LVP, and LVSP.

Group	Heart weight (mg)	Body weight (g)	HW/BW (mg/g)	LVP (mmHg)	LVSP (mmHg)
Sham	1.32 ± 0.12	499 ± 49.3	2.40 ± 0.11	110 ± 21.0	105 ± 16.7
TAC	1.40 ± 0.14	490 ± 41.2	3.02 ± 0.47^##	144 ± 23.9^##	133 ± 23.2^##
Captopril	1.36 ± 0.10	492 ± 35.2	2.64 ± 0.25*	127 ± 18.6**	116 ± 19.1*
QL-L	1.33 ± 0.14	500 ± 52.4	2.67 ± 0.31*	127 ± 13.9*	117 ± 18.6
QL-M	1.31 ± 0.20	503 ± 46.2	2.61 ± 0.35*	125 ± 18.7**	115 ± 13.9*
QL-H	1.28 ± 0.13	490 ± 42.0	2.54 ± 0.29**	119 ± 13.9**	103 ± 16.0**

Sham: control group; TAC: model group; QL-L: low-dose QL group; QL-M: medium-dose QL group; QL-H: high-dose QL group;
The Sham rats and TAC rats were treaded with vehicle (0.5%CMC-Na, 10 mL/kg/d); the low-dose QL group was treated with 0.25 g/kg/day QL: the medium-dose QL group was treated with 0.5 g/kg/day QL; the high-dose QL group was treated with 1 g/kg/day QL. Captopril group was treated with 6.25 mg/kg/day Captopril. Values were expressed as mean ± standard deviation. Compared with TAC, #P < 0.05, ##P < 0.01; compared with TAC, ∗P < 0.05, ∗∗P < 0.01.